Skip to content

Overview
Interest Rates
10Y Treasury
Stocks & Bonds
IPOs & Deals
News

Stocks & Bonds
/
Details

Loading security details…

Recent articles

Loading articles…

Data sources

Treasury yields: U.S. Department of the Treasury. Reference rates: Federal Reserve Bank of New York. Additional rates: FRED, Federal Reserve Bank of St. Louis (when configured). Quotes and company news: Finnhub (when configured). Headlines link to their original publishers.

Data sources, refresh intervals & status

Disclaimer

For information only; not investment advice. Data may be delayed, cached or incomplete. Each value shows its source, timestamp and status. Verify with the original source before acting.

IAM · Basis Point

Overview
Interest Rates
10Y Treasury
Stocks & Bonds
IPOs & Deals
News

Overview
Interest Rates
10Y Treasury
Stocks & Bonds
IPOs & Deals
News

IAMETF

IAM

Latest quote

$13.43−$0.85down 0.85 dollars−5.95%down 5.95 percent

Day rangeCurrent $13.43, between a low of $12.39 and a high of $13.57.

$12.39$13.57

52-week rangeCurrent $13.43, between a low of $13.02 and a high of $25.00.

$13.02$25.00

Open: $13.10
Previous close: $14.28
Day high: $13.57
Day low: $12.39

Delayed: Not a real-time value. Check the timestamp for when it was last updated.Source: Finnhub(opens in a new tab)Last updated Oct 30, 2026, 4:00 PM ETRetrieved 2:36 PM ET

Recent articles about IAM

YahooOct 26, 8:00 AM ETvia Finnhub
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers (opens Yahoo in a new tab)
SAN DIEGO, October 26, 2026--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinical data for IAM1363, a selective and brain-penetrant HER2…
- Markets
BenzingaOct 26, 4:05 AM ETvia Finnhub
Iambic Therapeutics Presents Updated Clinical Results From Its IAM1363 Inhibitor At ESMO Congress 2026

(opens Benzinga in a new tab)

Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinical data for IAM1363, a

Markets

YahooOct 18, 1:15 AM ETvia Finnhub

Iambic Therapeutics (IAM) Filed An IND For IAM217 (opens Yahoo in a new tab)

Iambic Therapeutics (NasdaqGS:IAM) submitted an Investigational New Drug application to the FDA for IAM217, a KIF18A inhibitor, in October 2026. IAM217 is described by the company as a brain penetrant KIF18A inhibitor designed for aggressive tumor types, including hard to treat…

YahooOct 17, 8:16 PM ETvia Finnhub

Iambic Therapeutics (IAM) Joins The Nasdaq Composite, Is The Stock Already Pricey? (opens Yahoo in a new tab)

Iambic Therapeutics (IAM) was just added to the Nasdaq Composite Index after a busy October that included its US$150 million IPO and a US$184.6 million shelf registration. The recent Nasdaq Composite inclusion builds on a sharp positive swing in Iambic Therapeutics’ trading…

Markets

SeekingAlphaOct 16, 8:30 PM ETvia Finnhub

U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings (opens SeekingAlpha in a new tab)

No IPOs are currently scheduled for the week ahead as the yearâs next mega IPO potentially comes into view. Read more here.

Live: Retrieved from the source within its refresh interval.Source: Finnhub(opens in a new tab)Latest Oct 26, 2026, 8:00 AM ETRetrieved 2:36 PM ETStale: not updated recently